Answers are grounded in this paper and cite their sources.
Background/Objectives: Immune checkpoint inhibitors (ICIs) have transformed cancer treatment by restoring antitumor immune activity, but disruption of immune tolerance may result in immune-related adverse events (irAEs) involving multiple organs. The marked variability in irAE occurrence and phenotype suggests that treatment-induced immune activation acts on a background of pre-existing biological susceptibility. This narrative review evaluates genetic and epigenetic factors associated with irAE susceptibility and examines their potential contribution to risk assessment and the broader biology of immune dysregulation. Methods: A narrative review of the literature was conducted using PubMed/MEDLINE, Scopus, and Web of Science. Studies addressing HLA polymorphisms, germline variants, polygenic risk, DNA methylation, histone and chromatin regulation, and non-coding RNAs in relation to irAEs were considered. Particular emphasis was placed on human evidence, reproducibility, methodological limitations, and translational relevance. Results: Genetic studies provide the strongest human evidence for a contribution of inherited variation to selected irAE phenotypes, particularly through HLA and other immunoregulatory loci. Polygenic approaches may capture susceptibility more broadly than individual variants, but their predictive performance and generalizability remain insufficiently established. Epigenetic mechanisms, including DNA methylation and non-coding RNAs such as miR-146a, add a potentially dynamic layer of immune regulation. Interpretation of these findings is complicated by differences in irAE phenotype, timing of sampling, treatment exposure, population background, and tissue or cellular composition. Biological associations have not yet been translated into clinically validated predictive tools. Conclusions: Genetic and epigenetic variation may contribute to the biological background underlying susceptibility to irAEs, but current evidence does not support routine molecular risk testing before ICI therapy. Future progress will depend on prospective, multicenter studies that combine standardized clinical phenotyping with pre-treatment genetic information and longitudinal molecular profiling. The ultimate value of these approaches will be determined not simply by their ability to predict irAEs, but by whether they improve individualized risk assessment and clinical decision-making.
No takes yet. Share an insight, caveat, or question.
Gromadzka et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: